Investors
Novo Nordisk: A Long-Term Hold Even At Current Valuations (NYSE:NVO) | Seeking Alpha
Share and ownership structure of Novo Nordisk
Novo Nordisk Stock: Growing Obesity Epidemic Will Generate Demand (NYSE:NVO) | Seeking Alpha
Mark Root - Director, Investor Relations - Novo Nordisk | LinkedIn
Novo Nordisk Annual Report 2012 by Novo Nordisk A/S - Issuu
Novo Nordisk A/S purchases B shares worth DKK 3,582 million from Novo Holdings A/S under the 2022 share repurchase programme
Contact our Novo Nordisk Investor Relations team
Contact our Novo Nordisk Investor Relations team
Novo Nordisk, citing strong Wegovy demand, doubles 2025 sales target for obesity franchise | Fierce Pharma
Contact our Novo Nordisk Investor Relations team
CSRWire - Novo Nordisk Releases Integrated Annual Report 2017
Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders | Business Wire
Novo Nordisk Publishes Integrated 2015 Annual Report
Novo Nordisk U.S. News & Media Hub | Novo Nordisk U.S.
Novo Nordisk Investor Relations Material - Quartr
Contact our Novo Nordisk Investor Relations team
f6k_01.jpg
Newly Released: Novo Nordisk Publishes Integrated 2019 Annua
Novo Nordisk Investor Relations Material - Quartr
